Metastatic renal cell carcinoma: Long-term survival after therapy with high-dose continuous-infusion interleukin-2

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Gold, Philip J ^a,b   Thompson, John A ^a   Markowitz, Daniel R ^a   Neumann, Stacy ^a   Fefer, Alexander ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Interleukin 2; Renal cell carcinoma

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEPHRECTOMY; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031431092     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Taneja SS, Pierce W, Figlin R et al. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Urology 1995;45:911-924.
2. Dillman RO, Oldham RK, Tauer KW et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 1991;9: 1233-1240.
3. Rosenberg S, Lotze M, Yang J et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
4. Atkins M, Sparano J, Fisher R et al. Randomized phase II trial of high dose interleukin either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11:661-670.
5. Fyfe G, Fisher R, Rosenberg S et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688-696.
6. Rosenberg S, Yang J, Topalian S et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-913.
7. Talmadge JE, Phillips H, Schindler J et al. Systemic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 1987;47:5725-5732.
8. Rosenberg S, Mule J, Spiess P et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 1985;161:1169-1188.
9. Thompson JA, Peace DJ, Klarnet JP et al. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol 1986;137:3675-3680.
10. Ettinghausen S, Rosenberg S. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 1986;46:2784-2792.
11. Thompson JA, Lee DJ, Lindgren CG et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989;49:235-240.
12. Thompson J, Shulman K, Benyunes M et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992;10:960-968.
13. Thompson J, Benyunes M, Bianco J et al. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells. Semin Oncol 1993;20:46-51.
14. Thompson J, Bianco J, Benyunes M et al. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 1994;54:3436-3441.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-481.
16. Gardner MJ, Altman DG. Calculating confidence intervals for proportions and their differences. In: Gardner MJ, Altman DG, eds. Statistics with Confidence. London: British Medical Journal, 1989:28-33.
17. Weiss GR, Margolis KA, Aronson FR et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-281.
18. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-632.
19. Philip T, Negrier S, Lasset C et al. Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br J Cancer 1993;68: 1036-1042.
20. Escudier B, Farace F, Theodore C et al. Traitment du cancer du rein metastatique avec un nouveau schema d'interleukine-2: experience de l'institut Gustave-Roussy. Bull Cancer (Paris) 1995;82: 296-302.
21. Geertsen P, Hermann G, Maase H et al. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. J Clin Oncol 1992;10:753-759.
22. Law T, Motzer R, Mazumder M et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76:824-832.
23. Negrier S, Escudier B, Lasset C et al. The FNCLCC Crecy Trial: interleukin 2 (IL2) + Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proceedings of ASCO 1996;15:629a.
24. McCabe MS, Stablein D, Hawkins MJ. The modified group C experience - phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proceedings of ASCO 1991;10:213.
25. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
26. Yang JC, Topalian SL, Parkinson D et al. A randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma - an interim report. J Clin Oncol 1994;12:1572-1576.
27. Figlin RA, Pierce WC, Belldegrun A. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Semin Oncol 1993;20: 11-15.
28. Dutcher J, Fisher R, Weiss G et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157-162.
29. Gitlitz B, Pierce W, Moldawer N et al. Long term follow-up and patterns of relapse in metastatic renal cell carcinoma (RCCa) using an outpatient regimen of low dose interleukin-2 (IL-2) and interferon-alpha (IFN): UCLA Kidney Cancer Program. Proceedings of ASCO 1994;13:802a.
30. Atzpodien J, Kirchner H, de Mulder P et al. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter phase II study. Cancer Biother 1993;8:289-300.
31. Schoof D, Terashima Y, Batter S et al. Survival characteristics of metastatic renal cell carcinoma patients treated with lymphokineactivated killer cells plus interleukin-2. Urology 1993;41:534-539.
32. 18F]-fluorodeoxyglucose positron emission tomography despite radiographic evidence suggesting persistent rumor: a case report. Am J Roentgenol 1997;169:1049-1050.